Vascular endothelial growth factor (VEGF)
1 -A, also referred to as vascular permeability factor, is a dimeric glycoprotein essential for many angiogenic processes in normal and abnormal states such as tumor vascularization (1) . VEGF-A exhibits two major biological activities: one is the capacity to stimulate vascular endothelial cell proliferation (2) (3) (4) , and the other is the ability to increase vascular permeability (5, 6) . Human VEGF-A has at least six subtypes due to the alternative splicing of a single gene, VEGF 121 , VEGF 145 , VEGF 165 , VEGF 183 , VEGF 189 , and VEGF 206 (1, 7) . Among them, VEGF 165 has the most potent biological activity and is the most abundant subtype in vivo with a few exceptions such as in placenta. VEGF-A binds to and activates two tyrosine kinase receptors, VEGF receptor (VEGFR)-1 (Flt-1) and VEGFR-2 (KDR/Flk-1 in mice) (1, 8) . In addition, VEGF 165 also binds another membrane protein, neuropilin-1 (NRP-1) (9) .
Currently, the mammalian VEGF family includes VEGF-A; placenta growth factor (PlGF); and VEGF-B, -C, and -D. PlGF and VEGF-B bind specifically to VEGFR-1 (10 -12) , whereas VEGF-C and VEGF-D bind and activate VEGFR-3 (Flt-4), regulating lymphangiogenesis as well as angiogenesis (13) . Homologs of VEGF have also been identified in the genome of the Parapoxvirus Orf virus and shown to have VEGF-like activities. VEGF-E is the collective term for a group of these proteins, and all VEGF-E variants studied bind VEGFR-2, but not VEGFR-1 or VEGFR-3 (14 -16) .
Homozygous loss of the VEGFR-1 or VEGFR-2 gene results in embryonic lethality between days 8.5 and 9.5, indicating that these VEGFRs play important roles in vasculogenesis and angiogenesis (17, 18) . VEGFR-2 Ϫ homozygous mice die due to a lack of endothelial cell growth and blood vessel formation as well as extremely poor hematopoiesis. On the other hand, VEGFR-1 Ϫ homozygous mice die due to an overgrowth of endothelial cells and disorganization of blood vessels. The different phenotypes of these VEGFR Ϫ homozygous mice suggest that VEGFR-2 is the major positive signal transducer, whereas VEGFR-1 has a negative regulatory role in angiogenesis early in embryogenesis. A VEGFR-2-selective VEGF mutant or VEGF-E (a VEGFR-2-specific ligand) is able to induce vascular permeability to an extent indistinguishable from that of wildtype VEGF 165 , whereas a VEGFR-1-selective VEGF mutant or PlGF (a VEGFR-1-specific ligand) has little or no direct permeability-enhancing activity (10, 11, 14, 19) . Therefore, not only physiological angiogenesis but also the enhancement of vascular permeability have been considered to be mediated through VEGFR-2 (but not VEGFR-1) activation. In contrast to the negative regulatory role of VEGFR-1 in physiological angiogenesis, recent studies have shown that VEGFR-1 signaling is important for angiogenesis and plasma extravasation under pathological conditions (20, 21) .
Recently, several VEGF-like proteins have been isolated from snake venoms (22, 23) and reported to have biological activity similar to VEGF 165 (24) . However, several fundamental questions remain unanswered. First, is the VEGF-like protein of snake venom a splicing variant of VEGF-A or not? Snakes should have VEGF-A for their own physiological angiogenesis because the VEGF-VEGFR system is well conserved among vertebrates. However, the relation between snake venom VEGF and VEGF-A is still unclear. Second, if the VEGF-like protein of snake venom is distinct from VEGF-A, what is the difference in biological activity and molecular mechanism between them? Assuming that snakes have two different VEGF-like molecules, there should be some advantage to the host or some reason why the snake utilizes these apparently similar molecules for different purposes, one as a toxin and another for physiological angiogenesis.
In this study, we carried out the purification and characterization of a novel VEGF-like protein from Trimeresurus flavoviridis (or Protobothrops flavoviridis) Habu snake venom. The Habu snake is a deadly poisonous snake found in Southeast Asia, whose envenomation causes severe hemorrhage. We demonstrate that T. flavoviridis snake venom VEGF (Tfsv-VEGF) is distinct from T. flavoviridis VEGF (TfVEGF)-A and that the dominant activation of VEGFR-1 and the less extensive activation of VEGFR-2 by TfsvVEGF result in marked vascular hyperpermeability and weak endothelial cell mitotic activity. Understanding the signaling mechanism utilized by TfsvVEGF enables one to recognize the importance of VEGFR-1 signaling in physiological vascular permeability.
EXPERIMENTAL PROCEDURES
Snake Venom and Cell Cultures-Venom was collected from T. flavoviridis Habu snakes inhabiting the Amami Oshima Islands in Japan and kept in a lyophilized state. Sf9 cells were cultured in EX-CELL 400 medium (JRH Biosciences). NIH3T3-NRP-1 cells were established as described previously (11) using the pCAG-NRP-1 plasmid. NIH3T3-VEGFR-1 cells (25), NIH3T3-VEGFR-2 cells (26) , and NIH3T3-NRP-1 cells were maintained in Dulbecco's modified Eagle's medium (Nissui Pharmaceutical) supplemented with 10% calf serum, 2 mM L-glutamine, 40 g/ml kanamycin, and 200 g/ml G418. Human umbilical vein endothelial cells (Kurabo Industries) were maintained in HuMedia-EG2 medium (Kurabo Industries) according to the manufacturer's instructions. Sinusoidal endothelial (SE) cells were isolated from rat liver as described (27) and grown in HuMedia-EG2 medium supplemented with 10 ng/ml recombinant human VEGF 165 (R&D Systems).
Antibodies-Polyclonal antisera against TfsvVEGF were raised in rabbits using a C-terminal 19-amino acid sequence (residues 104 -122) or a 20-amino acid sequence in strands ␤4 and ␤5 and loop 3 (residues 56 -75) as antigen. Rabbit polyclonal antisera to TfVEGF-A were generated against a synthetic peptide corresponding to the N terminus of TfVEGF-A (residues . The antisera to these peptides specifically recognized TfsvVEGF and TfVEGF-A, respectively, in Western blot analysis. Rabbit polyclonal antisera generated against a synthetic pep- tide of the kinase insert region of human VEGFR-2 (residues 947-966) (28) were used for Western blot analysis, and mouse anti-Flk-1 monoclonal antibody (A-3, Santa Cruz Biotechnology) was used for immunoprecipitation. Rabbit polyclonal antisera raised against the C-terminal domain of human VEGFR-1 (residues 1123-1338) (25) were used for immunoprecipitation, and rabbit anti-Flt-1 polyclonal antibody (C-17, Santa Cruz Biotechnology) was used for Western blot analysis. Rat anti-phospho-Tyr 1175 monoclonal antibody was generated against the keyhole limpet hemocyanin-conjugated phosphopeptide DGKDY-(PO 3 and D is A, T, or G) were designed based on sequences of VEGF genes highly conserved among various species to amplify the cDNA for Tfsv-VEGF or TfVEGF-A. Rapid amplification of cDNA ends of the 5Ј-or 3Ј-end was performed with these degenerate primers and anchor primers corresponding to the anchor sequence combined with the 3Ј-end of the oligo(dT) primer or the sequence involved in the 5Ј-end of the SMART IV oligonucleotide. The nucleotide sequences were determined using a BigDye Terminator cycle sequencing kit and an ABI310 automated DNA sequencer (Applied Biosystems). 
Expression and Purification of Recombinant TfVEGF-A-A DNA fragment encoding
TfVEGF-A was amplified by PCR using cDNA from T. flavoviridis livers and the primer set 5Ј-CGAATTCCGAGCAAAGA-AGAGAAGGCTTAAGAG-3Ј and 5Ј-GTGAAAAACCGAGGCGGCATC-ATCACCATCACCATTGAGCGGCCGCGAGCAGCCTT-3Ј, containing an EcoRI restriction site in the forward primer and six histidines as well as a NotI restriction site in the reverse primer. The PCR product was cloned into the pCR2.1-TOPO plasmid (Invitrogen). Plasmid DNA containing the TfVEGF 166 -His insert was digested with EcoRI and NotI enzymes. The excised insert was subcloned in the same site on the multicloning region of pVL1393 (Invitrogen), resulting in the pVL1393-TfVEGF 166 -His construct. Correct cloning was confirmed by sequencing. This transfer vector DNA was used for cotransfection into Sf9 cells along with the linearized baculovirus DNA BaculoGold (BD Biosciences) by calcium phosphate transfection. Amplification of the recombinant viruses and protein expression were carried out as described previously (29) .
The supernatant (150 ml) of cells infected with the TfVEGF 166 -His recombinant virus was collected, concentrated, and applied to a HisTrap HP column (Amersham Biosciences) previously equilibrated with 20 mM sodium phosphate, 0.5 M NaCl, and 200 mM imidazole (pH 7.4). Bound proteins were eluted with 20 mM sodium phosphate, 0.5 M NaCl, and 500 mM imidazole (pH 7.4); further concentrated; and buffer-exchanged into phosphate-buffered saline and 10% glycerol. The protein concentration was determined as described above.
Mass Spectrometry-Mass spectral analysis of the purified protein was performed as described previously (30) . Proteins were identified by comparing the molecular masses determined by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry with theoretical peptide masses from the deduced amino acid sequence determined previously.
Reverse Transcription-PCR Analysis-Poly(A) ϩ RNA from various T. flavoviridis organs was extracted with a FastTrack 2.0 kit and reverse-transcribed using a modified oligo(dT) primer and PowerScript reverse transcriptase (BD Biosciences). PCR was performed using the primer set for the TfsvVEGF gene (5Ј-TGGCAGTTGCCATCCTCTTC-TGCATC-3Ј and 5Ј-ACAAAGGGGAACCTGGCTCTCGG-3Ј) or the TfV-EGF-A gene (5Ј-ATGAACTTTCTGCTCACTTGGATCC-3Ј and 5Ј-TCA-CCGCCTCGGTTTTTCACATCT-3Ј). RNA levels were standardized to the T. flavoviridis ␤-actin gene.
Endothelial Cell Growth Assay-The human umbilical vein endothelial cell proliferation assay was carried out as described previously (14) . Cell numbers were determined using a CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer's directions. Rat liver SE cells were seeded at 1 ϫ 10 5 cells/well on 24-well collagen-coated plates. About six hours later, the medium was replaced with HuMedia-EG2 medium supplemented with aliquots of each fraction separated by FPLC or with VEGF 165 or TfsvVEGF, and the cells were incubated at 37°C for 72 h. Cell numbers were determined as described above.
Vascular Permeability Assay-The Miles assay in guinea pigs was performed as described previously (14) . The Miles assay in mice was performed as follows. Twelve-week-old female BALB/c mice (wild-type or VEGFR-1 tyrosine kinase-deficient homozygous (VEGFR-1 TKϪ/Ϫ )) were shaved, and 100 l of 1% Evans blue solution was injected in the tail vein. After 30 min, 100 ng of growth factor in 40 l of phosphatebuffered saline was given by intradermal injection into the mid-dorsum. Thirty minutes later, the skin was removed, cleaned of connective tissues, and photographed. The amount of dye extracted from the skin with formamide was quantitated by spectrophotometry at 620 nm.
Ligand reagents (Amersham Biosciences). The cell-surface receptor competition assay was performed as described previously (14) .
Heparin Affinity Chromatography-TfsvVEGF was applied to a HisTrap Heparin HP column previously equilibrated with 20 mM sodium phosphate (pH 7.2) and 150 mM NaCl. The column was washed with the same buffer, and the bound material was eluted by applying a linear NaCl gradient from 0.15 to 1.15 M at a flow rate of 1 ml/min using an FPLC system. Fractions (1 ml each) were collected and analyzed for the presence of TfsvVEGF by Western blotting with anti-TfsvVEGF antibody.
Immunodetection of VEGFR-1 or VEGFR-2 Phosphorylation-For in vivo phosphorylation, cells were starved overnight in 0.1% serum-containing medium and stimulated at 37°C with various concentrations of TfsvVEGF or VEGF 165 for 5 min. The cells were washed twice with ice-cold phosphate-buffered saline, lysed, and clarified by centrifugation as described previously (26) . For immunoprecipitation, cell lysates were mixed gently with the primary antibody conjugated to protein A or G-Sepharose beads (Amersham Biosciences) for 16 h at 4°C. The beads were washed five times with 1% Triton X-100 lysis buffer. The precipitated proteins were subsequently analyzed by Western blotting using specific antibodies as described above.
RESULTS

Protein Purification and Determination of the Entire cDNA
Sequence of TfsvVEGF-To clarify the molecular basis of the bleeding caused by T. flavoviridis envenomation, we investigated the effect of T. flavoviridis venom on angiogenesis and vascular permeability. During an investigation of the biological activity of T. flavoviridis venom for blood vessel structures, we found a protein that induced vascular hyperpermeability and the proliferation of primary SE cells. We purified this protein by FPLC using Superdex 200, Mono S, and Mono Q columns and the VEGFR-1 ligand-binding domain (Fig. 1, A-D) because we found that it was able to induce tyrosine autophosphorylation of VEGFR-2 and to bind soluble VEGFR-1 (data not shown). The purified protein was obtained with a yield of ϳ0.01% from total venom and migrated as three bands upon SDS-PAGE under reducing conditions (Fig. 1E) . After determining the entire sequence of the TfsvVEGF gene using the degenerate PCR method and venom gland cDNA ( Fig. 2A) , we analyzed each purified protein corresponding to the three bands by MALDI-TOF mass spectrometry and found that all three purified proteins were identical and that they were really encoded by the TfsvVEGF gene. We further confirmed that the protein was TfsvVEGF using anti-TfsvVEGF antibody (Fig.  1E) . TfsvVEGF was found to be a dimer composed of two subunits of ϳ12-14 kDa (Fig. 1E ) with no basic domain and showed 52% identity to human VEGF-A (Fig. 3A) . All eight cysteine residues of the central cysteine knot motif characteristic of the VEGF family proteins were completely conserved in TfsvVEGF (Fig. 3A) . The N-linked glycosylation site present in both human VEGF-A and TfVEGF-A (Fig. 3A) was absent in TfsvVEGF. Moreover, we could not obtain any evidence for O-glycosylation of TfsvVEGF (data not shown).
TfsvVEGF Is Distinct from TfVEGF-A-To examine whether the T. flavoviridis Habu snake has a VEGF-A gene in addition to the svVEGF gene, we attempted to isolate the putative TfVEGF-A gene from kidney cDNA using degenerate PCR and found TfVEGF-A (Fig. 2B) , which is 71% identical at the amino acid level to human VEGF-A (Fig. 3A) . Among the six splice variants of human VEGF-A, VEGF 121 , VEGF 165 , and VEGF 189 are considered to be the major isoforms. Here, we identified three major isoforms of TfVEGF-A, TfVEGF 122 , TfVEGF 166 , and TfVEGF 190 , and revealed that they are conserved even in the T. flavoviridis Habu snake. Reverse transcription-PCR analysis using RNA from various T. flavoviridis tissues demonstrated that the TfVEGF-A gene was expressed in most of the tissues, but the TfsvVEGF gene was restricted to the venom gland (Fig.  3B) . A phylogenetic tree of representative VEGF cDNA sequences revealed that the svVEGF gene is distinct from the VEGF-A gene (Fig. 3C) . These results indicate that the T. flavoviridis Habu snake utilizes at least two different VEGF-like molecules (TfsvVEGF and TfVEGF-A) for different purposes, one as a toxin and the other for normal angiogenesis.
T. flavoviridis Venom Contains TfsvVEGF in Much More Abundant Amounts than TfVEGF-A-Since the expression of
the TfVEGF-A gene was relatively higher in the venom gland than in other organs (Fig. 3B) , we examined whether TfVEGF-A, in addition to TfsvVEGF, is present in T. flavoviridis venom. Considering the molecular mass of TfsvVEGF or TfVEGF-A as a dimer, we separated proteins of 15-60 kDa (Fraction B) (Fig. 1A ) from total venom using gel filtration for this analysis. Western blot analysis revealed that three isoforms of TfVEGF-A were also present in the venom; however, the relative abundance of TfsvVEGF was about 60 times higher than that of TfVEGF-A (Fig. 3D) . Therefore, although TfVEGF 166 was found to bind both human VEGFR-1 and VEGFR-2 ( Fig. 3E) and was expected to have some biological activity on mammalian endothelial cells, it may not significantly affect the biological activity of TfsvVEGF in envenomation.
TfsvVEGF Induces Strong Vascular Permeability but Weak Endothelial Cell Proliferation-We next investigated the difference in biological activity and receptor specificity between TfsvVEGF and VEGF-A. TfsvVEGF was found to have the same level of activity for vascular permeability as human VEGF 165 in guinea pigs using the Miles assay (Fig. 4, A and B) . However, TfsvVEGF had almost 10-fold less SE cell mitotic activity than VEGF 165 (Fig. 4C) . We also confirmed the weak endothelial cell mitotic activity of TfsvVEGF in a proliferation assay of human umbilical vein endothelial cells (data not shown). The concentration of TfsvVEGF in crude venom was estimated at ϳ60 -100 ng/ml (2.2-3.7 nM) according to the yield of this protein. This concentration is consistent with both the ineffective concentration of TfsvVEGF for endothelial cell proliferation and the effective concentration for vascular permeability. Therefore, we speculate that T. flavoviridis Habu snakes actually utilize TfsvVEGF for enhancing toxicity at an optimum concentration for the induction of vascular permeability, but not angiogenesis.
TfsvVEGF Binds VEGFR-1 with High Affinity but Binds VEGFR-2 with Low Affinity-To investigate the binding of
TfsvVEGF to VEGFR-1, -2, and -3 and NRP-1, TfsvVEGF was precipitated by various VEGFR/Fc or NRP-1/Fc fusion proteins bound to protein A-Sepharose. Western blot analysis using anti-TfsvVEGF antibody revealed that TfsvVEGF did not bind VEGFR-3 or NRP-1 but bound VEGFR-1 and VEGFR-2 (Fig.  5A) . We next tested whether TfsvVEGF binds to heparin. When applied to a HisTrap Heparin HP column, TfsvVEGF was eluted in the presence of ϳ0.6 M NaCl (Fig. 5B) . This result indicates that TfsvVEGF is able to bind heparin, although this protein does not have a basic domain. We further examined the ability of TfsvVEGF to bind cell surface-expressed receptors using NIH3T3 cells overexpressing human VEGFR-1 or VEGFR-2 or mouse NRP-1 in a binding competition assay. As expected, even a 1000-fold excess of TfsvVEGF could not inhibit the binding of 125 I-VEGF to NIH3T3-NRP-1 cells (Fig.  5C ). TfsvVEGF competed with 125 I-VEGF to bind both VEGFR-1 and VEGFR-2, but its effect differed between the two receptors. The competition by TfsvVEGF for 125 I-VEGF binding to VEGFR-1 showed kinetics comparable with those of unlabeled VEGF 165 . The half-maximum inhibitory concentrations (IC 50 ) for TfsvVEGF and VEGF 165 were estimated to be 30 and 12 ng/ml, respectively (Fig. 5D) . However, the competition by TfsvVEGF for binding to VEGFR-2 showed significantly different kinetics from those of unlabeled VEGF 165 . The IC 50 for TfsvVEGF was estimated to be 254 ng/ml, whereas that for VEGF 165 was 13 ng/ml (Fig. 5E) . These results indicate that TfsvVEGF can bind both VEGFR-1 and VEGFR-2, but the affinity of TfsvVEGF for VEGFR-2 is an order of magnitude weaker than that of human VEGF 165 , although the binding affinity for VEGFR-1 is similar between these two ligands. 165 -To examine the ability of TfsvVEGF to activate VEGFR-1 and VEGFR-2, we tested whether TfsvVEGF could stimulate autophosphorylation of these receptors. NIH3T3-VEGFR-1 or NIH3T3-VEGFR-2 cells were stimulated with var- FIG. 7 . Amplification of VEGFR-2-mediated biological activity by VEGFR-1 signaling is different in vascular permeability enhancement and endothelial cell proliferation. A, proliferation assay with SE cells using PlGF and VEGF-E at various ratios. SE cells were cultured with the indicated ratios of PlGF and VEGF-E at a total concentration of 40 ng/ml for 72 h, and cell growth was monitored. The proliferation of SE cells at 40 ng/ml TfsvVEGF was also examined. B and C, vascular permeability in response to the combination of PlGF and VEGF-E. B, representative images of the skin of guinea pigs used in the Miles assay showing the vascular permeability in response to the indicated ratios of PlGF and VEGF-E at a total concentration of 80 ng/0.2 ml. The vascular permeability induced by 80 ng of TfsvVEGF/0.2 ml was also examined. PBS, phosphate-buffered saline; rhVEGF165, recombinant human VEGF 165 . C, amount of dye extracted from the skin with formamide was quantitated by spectrophotometry at 620 nm. Results represent the means Ϯ S.D. of triplicate experiments.
TfsvVEGF Stimulates Autophosphorylation of VEGFR-2 Weakly but That of VEGFR-1 at the Same Level as VEGF
ious concentrations of VEGF 165 or TfsvVEGF for 5 min. Consistent with the binding affinity, TfsvVEGF had almost 10-fold less ability to induce autophosphorylation of VEGFR-2, especially at Tyr 1175 on VEGFR-2, which is crucial for endothelial cell proliferation (28), compared with VEGF 165 (Fig. 6B) , but was able to induce autophosphorylation of VEGFR-1 at the same level as VEGF 165 (Fig. 6A) .
High Affinity for VEGFR-1 and Low Affinity for VEGFR-2 Are Responsible for the Vascular Permeability-dominant Effect
Induced by TfsvVEGF-To determine whether this unique binding affinity of TfsvVEGF influences the strong enhancing effect on vascular permeability but weak activity for angiogenesis, we first performed a proliferation assay of SE cells and the Miles assay in guinea pigs using PlGF as a VEGFR-1-specific ligand (10) and VEGF-E NZ-7 as a VEGFR-2-specific ligand (14) . The sum concentration of the two ligands was fixed, whereas the ratio of the ligands was changed. In the proliferation assay using these ligands at a concentration of 40 ng/ml, there was a good correlation between proliferation and the ratio of VEGF-E NZ-7 (the level of VEGFR-2 activation), although VEGFR-1 signaling had an additive effect. A maximum mitotic effect was observed when the ratio of PlGF to VEGF-E NZ-7 was 2:6 ( Fig.  7A) . However, the enhancement of vascular permeability was intensified by the activation of VEGFR-1 more than the proliferation of SE cells upon some active signaling from VEGFR-2. Maximum vascular hyperpermeability was observed when the ratio of PlGF to VEGF-E NZ-7 was 5:3 (Fig. 7, B and C) . To exclude the possibility of saturation, we performed these experiments at half-concentrations of these ligands and obtained basically the same results (data not shown). We next performed the Miles assay using VEGFR-1 tyrosine kinase-deficient homozygous (VEGFR-1 TKϪ/Ϫ ) mice (31) to confirm the involvement of VEGFR-1 signaling in the enhancement of vascular permeability by TfsvVEGF. In wild-type mice, 100 ng of human VEGF 165 or TfsvVEGF induced vascular hyperpermeability to a similar extent (Fig. 8, A and B) . In VEGFR-1 TKϪ/Ϫ mice, however, the effect on vascular permeability of TfsvVEGF was significantly weaker than that of VEGF 165 (Fig. 8, A and B) . These results indicate that the dominant activation of VEGFR-1 and the less extensive activation of VEGFR-2 by TfsvVEGF result in the strong activity promoting vascular permeability and the weak endothelial cell mitotic activity of this protein. This affinity is thought to be a key mechanism in the enhancement of the toxic effect with less angiogenesis.
DISCUSSION
In this study, we have demonstrated that TfsvVEGF is a different molecule from TfVEGF-A and is present in T. flavoviridis venom in much more abundant amounts than TfVEGF-A. We have also shown that the unique binding affinity of TfsvVEGF, i.e. high affinity for VEGFR-1 but low affinity for VEGFR-2, leads to the unique and purposive biological activity induced by TfsvVEGF: strong enhancement of vascular permeability but weak stimulation of endothelial cell proliferation.
Previous studies have described the identification of VEGFlike proteins from snake venom: hypotensive factor from Vipera aspis aspis venom (22) and snake venom VEGF from Bothrops insularis (23) . Although they were reported to induce vascular permeability and proliferation of vascular endothelial cells, the precise molecular mechanism involved remained unclear. During the course of our attempt to clarify the molecular actions of TfsvVEGF, two novel VEGF-like proteins derived from snake venom were reported by two groups, viz. ICPP (increasing capillary permeability protein) from Vipera lebetina venom (24) and vammin from Vipera ammodytes ammodytes venom (32) . Both ICPP and vammin stimulate the proliferation of vascular endothelial cells ϳ1.5 times more potently than VEGF 165 . Furthermore, vammin binds VEGFR-2-IgG with high affinity as well as VEGF 165 , but does not interact with VEGFR-1-IgG at all. These biological characteristics are significantly different from those of TfsvVEGF. Except for snake venom VEGF from Bothrops snakes, all VEGF-like proteins from snake venoms previously reported were isolated from the Viperinae subfamily (vipers), which is different from the Crotalinae subfamily (pit vipers), including T. flavoviridis. Therefore, we can conclude that snake venom-derived VEGF-like proteins have a variety of biological characteristics reflecting the divergence in the classification of the host snake and that TfsvVEGF is a novel type of VEGF-related protein distinct from other snake venom-derived VEGF-like proteins described previously.
The crystal structure of VEGF-A bound to the second Ig-like domain of VEGFR-1 (33) reveals that both the surface of the ligand and the surface of the receptor are rather flat and that the interface is dominated by hydrophobic contacts, which made up almost 70% of the total buried surface. The only direct polar interaction is a bidentate set of charge-mediated hydrogen bonds between the side chains of Arg 224 of VEGFR-1 and Asp 63 of VEGF-A. Within 10 hydrophobic residues exposed on the VEGFR-1-binding surface of VEGF 165 , nine residues are completely or highly conserved in TfsvVEGF with respect to hydrophobicity. Asp 63 of VEGF 165 is also conserved in Tfsv-VEGF (Fig. 3A) . Previous analysis of the VEGF 165 , and two of these replacements are also accompanied by changes in electric charge (Fig. 3A) . These changes are considered to be critical for tight binding to VEGFR-2 and result in the weak binding affinity of TfsvVEGF for VEGFR-2.
A previous study demonstrated that VEGF-induced vascular permeability and angiogenesis are mediated through the activation of VEGFR-2, but not VEGFR-1 (19) . Interestingly, despite its strong effect on vascular permeability, TfsvVEGF bound and activated VEGFR-2 an order of magnitude weaker compared with VEGF 165 , and in addition, it was unable to bind NRP-1, which can enhance the binding of VEGF 165 to VEGFR-2 (9). These results suggest the importance of VEGFR-1 signaling in the biological activity induced by Tfsv-VEGF. It has been shown that, unlike other representative growth factor receptor tyrosine kinases, VEGFR-2 utilizes the phospholipase C␥/protein kinase C/Raf/mitogen-activated protein kinase pathway, which is activated by the binding of phospholipase C␥ to phospho-Tyr 1175 on VEGFR-2, as the major signaling pathway for the proliferation of endothelial cells (28, 37) . Although the binding site for phospholipase C␥ on VEGFR-1 is not fully understood (38, 39) , we have shown that Tyr 1169 , a minor autophosphorylation site on VEGFR-1, is an important binding site for phospholipase C␥ (40) . In contrast, Tyr 1213 and Tyr 1309 are major autophosphorylation sites on VEGFR-1 (39 -42) . Considering these findings, it is reasonable that the VEGFR-1-dominant activation by TfsvVEGF leads only to weak mitogenesis of endothelial cells.
To elucidate the molecular mechanism of the unique activity induced by TfsvVEGF, first, we focused on the relationship between the biological activity and the ratio of VEGFR-1 to VEGFR-2 signaling through homodimeric receptors activated by specific ligands, PlGF and VEGF-E NZ-7 (Fig. 7, A-C) . In vascular permeability or proliferation assay using these specific ligands, we do not need to consider the "decoy" function of VEGFR-1 or the heterodimeric receptors. Through this simplified model, we have demonstrated that the proliferation of endothelial cells depended mainly on VEGFR-2 signals, whereas the enhancement of vascular permeability was strongly potentiated by VEGFR-1 signals. Second, in Miles assays using wild-type or VEGFR-1 TKϪ/Ϫ mice, which are an ideal in vivo model to analyze the role of VEGFR-1 signaling under physiological conditions, we confirmed that TfsvVEGF utilized VEGFR-1-dominant signals to induce vascular permeability, whereas VEGF 165 utilized VEGFR-2-dominant signals (Fig. 8, A and B) .
The involvement of VEGFR-1 signaling in VEGF-induced vascular permeability has been unclear. Our results clearly indicate the synergic effect of VEGFR-1 and VEGFR-2 activation on physiological vascular permeability. This is the first report describing the importance of VEGFR-1 signaling in vascular permeability as well as the difference in signaling properties involving VEGFR-1 and VEGFR-2 between vascular permeability and mitogenesis (Fig. 9) . A previous study demonstrated that some VEGF 165 mutants with very low affinity for VEGFR-2 can enhance vascular permeability as strongly as VEGF 165 without effective mitogenesis of endothelial cells (43) . Although the possibility of VEGFR-1 signaling was not clearly addressed, these VEGF mutants might be similar in character to TfsvVEGF. Recently, inter-and intramolecular VEGFR cross-talk was reported to enhance angiogenesis (42) . Our results suggest the existence of intra-or intermolecular crosstalk between VEGFR-1 and VEGFR-2 not only in angiogenesis but also in vascular permeability. In addition, this synergic effect of VEGFR-1 and VEGFR-2 on vascular permeability may partly explain the different phenotypes of VEGF-A and VEGF-E transgenic mice ( Fig. 9) : edematous lesions and hemorrhagic spots on the ear and in other dermal tissues reported as side effects in VEGF-A transgenic mice (44) were not detectable in VEGF-E transgenic mice (45) .
Recently, novel strategies aimed at improving drug penetration in tumors through vascular targeting have been reported (46) . Since TfsvVEGF is a potent inducing factor selective for vascular permeability, it can be applied for clinical use to improve the penetration of anticancer agents in tumors by increasing tumor vessel permeability without inducing effective tumor angiogenesis. 
